Novavax IncNVAX
Price$10.60

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $413.8M-39.3% YoYTTM through 30 Jun 2026
Net Income -$247.7MTTM through 30 Jun 2026
Free Cash Flow -$47.9MTTM through 30 Jun 2026

Margins

Current
Gross Margin78.0%
EBITDA Margin-49.8%
Operating Margin-11.1%
Net Margin-59.9%

Returns

129.9%ROE
-25.9%ROA

Balance Sheet Health

Debt / Equity-2.28x
Current Ratio2.33x
Net Debt-$499.3Mnet cash position
Cash & Equivalents$191.5M

Quality Metrics

Altman Z-Score-5.67
Piotroski F-Score1 / 9
FCF Margin-11.6%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $1.1B
Diluted EPS-$1.35TTM
'19'20'21'22'23'24'25
FY2025: $2.54

Dividend

No dividend

Capital Allocation

R&D Spend$340.3M
Capex Intensity2.6%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.